Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

GlaxoSmithKline Seeking Acquisition in Turkey, Hurriyet Reports

Jan. 29 (Bloomberg) -- GlaxoSmithKline Plc, the U.K.’s largest drugmaker, is seeking an acquisition in Turkey as it struggles to become profitable in the country, Hurriyet said, citing the company’s emerging markets president.

Potential targets include producers of cardiovascular drugs or businesses with production facilities that would add value to Glaxo’s operations, Hurriyet cited Abbas Hussain as saying.

Glaxo has failed to make a profit or increase revenue in Turkey in the past three years as a result of the country’s drug pricing policy, which has caused the company to cut costs and refrain from adding staff, Abbas told the newspaper. The drugmaker remains upbeat on its prospects there, he said.

Glaxo is evaluating options and many companies in Turkey fit its criteria, though finding one that’s for sale is difficult, Hurriyet cited Abbas as saying.

To contact the reporter on this story: Benjamin Harvey in Istanbul at

To contact the editor responsible for this story: Gavin Serkin at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.